|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
In this study, we tested genetic association of ATF4 and ATF5 genes with bipolar disorder by a case-control study in Japanese population (438 patients and 532 controls) and transmission disequilibrium test in 237 trio samples from NIMH Genetics Initiative Pedigrees.
|
17346882 |
2007 |
|
Bipolar Disorder
|
0.310 |
GeneticVariation
|
disease |
LHGDN |
In this study, we tested genetic association of ATF4 and ATF5 genes with bipolar disorder by a case-control study in Japanese population (438 patients and 532 controls) and transmission disequilibrium test in 237 trio samples from NIMH Genetics Initiative Pedigrees.
|
17346882 |
2007 |
|
Bipolar Disorder
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
In this study, we tested genetic association of ATF4 and ATF5 genes with bipolar disorder by a case-control study in Japanese population (438 patients and 532 controls) and transmission disequilibrium test in 237 trio samples from NIMH Genetics Initiative Pedigrees.
|
17346882 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consistent DN-ATF5 affecting tumor cell survival by suppressing CEBPB and CEBPD function, DN-ATF5 interferes with CEBPB and CEBPD transcriptional activity, while CEBPB or CEBPD knockdown promotes apoptotic death of multiple cancer cells lines, but not of normal astrocytes.
|
31676720 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although ATF5 mRNA expression in GBM showed a considerable fluctuation range, groups of varying biological behavior, that is, local/multifocal growth or primary tumor/relapse and the tumor localization at diagnosis, were not significantly different.
|
30584325 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It can serve as a crucial tumor suppressor in regulating the ATF5-regulated growth of malignant glioma.
|
28595907 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Preclinical assessment of a systemically deliverable dominant-negative ATF5 (dnATF5) biologic has found that targeting ATF5 results in tumor regression and tumor growth inhibition of glioblastoma xenografts in mouse models.
|
29137451 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these findings suggest that ATF5 plays an important role in enhancing mammary tumor cells overall aggressiveness and in promoting mammary tumor growth and emphasize the possible benefit of anti-ATF5 therapy in breast cancer patients, particularly, against tumors characterized with the positive expression of cell surface CD24.
|
28785242 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The nanostructure carrying ATF5 siRNA exerts remarkable RNA-interfering efficiency, increases glioblastoma cell apoptosis and inhibits tumour cell growth both in vitro and in xenograft tumour models.
|
28489075 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo, CP-d/n-ATF5-S1 attenuated tumor growth as a single compound in glioblastoma, melanoma, prostate cancer, and triple receptor-negative breast cancer xenograft models.
|
27126996 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, d/n-ATF5 induction after tumor formation led to regression/eradication of detectable gliomas without evident damage to normal brain cells in all 24 mice assessed.
|
21725368 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, normal astrocytes and neurons do not appear to require ATF5 for survival, indicating that it may be a selective target for treatment of glioblastomas and other neural neoplasias.
|
19046351 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By quantitative reverse transcription-PCR, profound down-regulations of ATF5 were further suggested in 78% of HCC tumors (60 of 77 cases) compared to their adjacent nontumoral liver (P = 0.0004).
|
18701499 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a proof-of-principle experiment, retroviral delivery of a function-blocking mutant form of ATF5 into a rat glioma model evokes death of the infected tumor cells, but not of infected brain cells outside the tumors.
|
16170340 |
2006 |
|
Glioblastoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
GBM patients were allocated to a low and a high ATF5 expression group by the median ATF5 overexpression compared to NB.
|
30584325 |
2018 |
|
Adult Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Expression of activating transcription factor 5 (ATF5) is increased in astrocytomas of different WHO grades and correlates with survival of glioblastoma patients.
|
30584325 |
2018 |
|
Childhood Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Expression of activating transcription factor 5 (ATF5) is increased in astrocytomas of different WHO grades and correlates with survival of glioblastoma patients.
|
30584325 |
2018 |
|
Glioblastoma Multiforme
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
GBM patients were allocated to a low and a high ATF5 expression group by the median ATF5 overexpression compared to NB.
|
30584325 |
2018 |
|
Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Preclinical assessment of a systemically deliverable dominant-negative ATF5 (dnATF5) biologic has found that targeting ATF5 results in tumor regression and tumor growth inhibition of glioblastoma xenografts in mouse models.
|
29137451 |
2017 |
|
Glioblastoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
The nanostructure carrying ATF5 siRNA exerts remarkable RNA-interfering efficiency, increases glioblastoma cell apoptosis and inhibits tumour cell growth both in vitro and in xenograft tumour models.
|
28489075 |
2017 |
|
Adult Glioblastoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
The nanostructure carrying ATF5 siRNA exerts remarkable RNA-interfering efficiency, increases glioblastoma cell apoptosis and inhibits tumour cell growth both in vitro and in xenograft tumour models.
|
28489075 |
2017 |
|
Adult Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Preclinical assessment of a systemically deliverable dominant-negative ATF5 (dnATF5) biologic has found that targeting ATF5 results in tumor regression and tumor growth inhibition of glioblastoma xenografts in mouse models.
|
29137451 |
2017 |
|
Childhood Glioblastoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
The nanostructure carrying ATF5 siRNA exerts remarkable RNA-interfering efficiency, increases glioblastoma cell apoptosis and inhibits tumour cell growth both in vitro and in xenograft tumour models.
|
28489075 |
2017 |
|
Childhood Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Preclinical assessment of a systemically deliverable dominant-negative ATF5 (dnATF5) biologic has found that targeting ATF5 results in tumor regression and tumor growth inhibition of glioblastoma xenografts in mouse models.
|
29137451 |
2017 |
|
Glioblastoma Multiforme
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
The nanostructure carrying ATF5 siRNA exerts remarkable RNA-interfering efficiency, increases glioblastoma cell apoptosis and inhibits tumour cell growth both in vitro and in xenograft tumour models.
|
28489075 |
2017 |